How Drug Marketing undermines Patient Safety and Public Health

The Inverse Benefit Law

Abstract

The inverse benefit law highlights the need for comparative effectiveness research and other reforms to improve evidence-based prescribing.

Recent highly publicized withdrawals of drugs from the market because of safety concerns raise the question of whether these events are random failures or part of a recurring pattern. The inverse benefit law, inspired by Hart’s inverse care law, states that the ratio of benefits to harms among patients taking new drugs tends to vary inversely with how extensively the drugs are marketed.

The law is manifested through six basic marketing strategies:

  1. reducing thresholds for diagnosing disease,
  2. relying on surrogate endpoints,
  3. exaggerating safety claims,
  4. exaggerating efficacy claims,
  5. creating new diseases,
  6. and encouraging unapproved uses.

The inverse benefit law highlights the need for comparative effectiveness research and other reforms to improve evidence-based prescribing.

NCBI Sources:

All our posts tagged Big Pharma – Doctors – Drug Money –Medical Representatives – Pharmaceutical Industry

Author: DES Daughter

Activist, blogger and social media addict committed to shedding light on a global health scandal and dedicated to raise DES awareness.

2 thoughts on “How Drug Marketing undermines Patient Safety and Public Health”

Have your say! Share your views

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.